research The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
Search
for
Sort by
Research
780-810 / 1000+ results 
research Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
Mycophenolate mofetil can effectively treat autoimmune hepatitis when standard drugs fail.
research Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
research Hormone replacement therapy and COVID-19 outcomes in solid organ transplant recipients compared with the general population
Hormone replacement therapy may lower the risk of severe COVID-19 outcomes in non-immunosuppressed people and male organ transplant recipients.
research Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
research RU 58841-myristate–prodrug development for topical treatment of acne and androgenetic alopecia.
RUM-loaded SLN shows promise for treating acne and hair loss topically.
research Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
research 60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials
Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
research Topical Drugs Regrow Hair In Mice
Certain topical drugs can regrow hair in mice.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
research Autoimmunity and clinical pathology amelioration in SLE by Dexamethasone primed Mesenchymal Stem Cell derived conditioned media
Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.
research 896 Androgens activate lipogenesis through an AKT-independent mTOR pathway stimulation and a limitation of autophagy in an androgen-sensitive sebocyte cell line
Dihydrotestosterone (DHT) increases oil production in skin cells by activating mTOR, and mTOR inhibitors can reduce this effect.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Refractory dissecting cellulitis of the scalp treated with risankizumab: 2 case reports
Risankizumab may help manage symptoms of dissecting cellulitis of the scalp.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
research A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
Ritlecitinib was generally well tolerated in children with alopecia areata.
research Poster Presentations
Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
Many drugs can cause lipid metabolism issues, and labels need better warnings.
research Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication
Nirogacestat can cause severe skin issues like hidradenitis suppurativa.
research Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency Due to an Interaction Between Fluticasone and Ritonavir
A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
research Selective inhibition of glucuronidation and sulfation in vitro and in vivo
research Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.